H. Wedemeyer Et Al. , "Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia," 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , vol.44, Massachusetts, United States Of America, 2006
Wedemeyer, H. Et Al. 2006. Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia. 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , (Massachusetts, United States Of America).
Wedemeyer, H., Yurdaydin, C., Zachou, K., Erhardt, A., Drebber, U., Cakaloglu, Y., ... Degertekin, H.(2006). Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia . 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America
Wedemeyer, Heiner Et Al. "Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia," 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 2006
Wedemeyer, Heiner Et Al. "Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia." 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , Massachusetts, United States Of America, 2006
Wedemeyer, H. Et Al. (2006) . "Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia." 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , Massachusetts, United States Of America.
@conferencepaper{conferencepaper, author={Heiner Wedemeyer Et Al. }, title={Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia}, congress name={57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases}, city={Massachusetts}, country={United States Of America}, year={2006}}